Novo-Nordisk stock gains as Wegovy weight-loss pill launches in Germany

Novo-Nordisk stock is in focus as the company launches its Wegovy weight-loss pill in Germany, adding a new oral GLP-1 option in Europe while recent quarterly figures show continued growth in obesity treatments.

Novo-Nordisk stock (ISIN DK0062498333) is drawing attention on September 1, 2026 as the Danish pharmaceutical group rolls out its Wegovy weight-loss pill in Germany, the first European Union market to receive the oral version of its flagship obesity drug. According to a report by Reuters dated September 1, 2026, Novo-Nordisk executives previously indicated that the Wegovy pill had already captured about 90% of the oral obesity market when the company discussed second-quarter results in August 2026. The Reuters coverage underscores how strongly the new formulation has been received globally.

Wegovy pill launch and German market impact

The launch of the Wegovy pill in Germany marks a significant expansion of Novo-Nordisk's GLP-1 obesity franchise into a major European market. As summarized by financial portal MarketScreener on September 1, 2026, Germany is the first EU country in which the oral Wegovy treatment is introduced, following earlier launches in the United States, the United Kingdom and the United Arab Emirates. MarketScreener notes that Germany is thus the first EU market for the pill.

In Germany, the retail pharmacy price of the Wegovy injection pen typically ranges between EUR 170 and EUR 280 per package depending on dosage, and according to MarketScreener this sets the reference for the pill's pricing as well. By aligning the pill price with the established injection price range of roughly EUR 170 to EUR 280, Novo-Nordisk aims to position the oral formulation as a comparable alternative rather than a premium product in the local market. For investors, the expansion into Germany combines a new revenue stream with strategic reinforcement of the overall Wegovy brand.

Recent quarter figures and GLP-1 obesity franchise

From a fundamentals perspective, recent quarterly results underline the growing importance of GLP-1 obesity drugs for Novo-Nordisk. According to an overview published by Seeking Alpha on August 31, 2026, Novo-Nordisk reported that its second-quarter 2026 net sales rose by 7% at constant currency, and the company raised its full-year 2026 guidance for the second time during the year. The Seeking Alpha analysis highlights that oral Wegovy has already passed 5 million prescriptions since launch, with weekly prescription volumes of about 265,000 as of mid-July 2026.

The 7% net sales increase at constant currency in the second quarter of 2026, combined with the repeated upward revision of full-year 2026 guidance, demonstrates that obesity treatments remain one of the main growth drivers for Novo-Nordisk. At the same time, Seeking Alpha notes that Novo-Nordisk shares temporarily fell by up to 6% following the release of the quarter due to mixed headline figures, showing that investors are closely scrutinizing both growth and profitability. In this context, the fact that oral Wegovy has surpassed 5 million prescriptions, with about 265,000 weekly prescriptions in mid-July 2026, gives a clear quantitative indication of how rapidly the franchise is scaling.

DACH angle and cross-market listings

For investors in the DACH region, Novo-Nordisk is present via cross-market listings and trading venues. MarketScreener data show that Novo-Nordisk shares trade on Cboe Europe with the symbol 0QIU, quoted at 43.70 EUR as of the closing session on August 31, 2026. The MarketScreener quote page lists the last price at 43.70 EUR for August 31, 2026, with the same level repeated over the previous several sessions, indicating a stable cross-market reference price for DACH investors via the Cboe Europe listing.

At the same time, MarketScreener quotes the primary Novo-Nordisk listing at 292.40 DKK as the last closing price and a current indicative price around 292.15 DKK to 292.90 DKK on September 1, 2026, corresponding to a market capitalization of about DKK 201 billion, or approximately USD 1,031 billion, as compiled in the same overview. The Italian MarketScreener version presents a last closing price of 292.40 DKK with an indicative price of 291.98 DKK on September 1, 2026, and a market capitalization of DKK 201 billion. This positions the current share price close to the average analyst price target of 309.73 DKK cited on the same page, implying roughly 6% upside to the consensus target.

Obesity treatments and GLP-1 competition

The Wegovy pill launch in Germany occurs amid intense competition in the GLP-1 obesity drug market. Seeking Alpha points out that the GLP-1 obesity segment is becoming more crowded, with Novo-Nordisk and Eli Lilly both expanding their portfolios and indications. In its August 31, 2026 article, Seeking Alpha notes that Eli Lilly's GLP-1 products, including its weight-loss injections, have contributed to a broader market in which oral and injectable therapies coexist, and that Novo-Nordisk must defend its leadership against these rivals. The observation that Novo-Nordisk shares fell as much as 6% when the second-quarter 2026 results were released underlines how sensitive the market has become to expectations on volume growth, margins and future indications.

In parallel, other news sources highlight the medical potential of GLP-1 weight-loss drugs beyond obesity. A Devdiscourse article updated on September 1, 2026 discusses clinical data showing that GLP-1 medicines can be effective even at low starter doses in weight-loss treatments, suggesting that titration strategies and dosing flexibility may further improve patient tolerability and access. The Devdiscourse report broadens the context for Novo-Nordisk's GLP-1 portfolio, in which semaglutide underpins both Ozempic for diabetes and Wegovy for obesity.

Representative product: Wegovy obesity treatment

Wegovy, a semaglutide-based treatment for obesity, is the representative product at the center of Novo-Nordisk's current expansion strategy. The recent launch of the Wegovy pill in Germany adds an oral formulation to the injectable pen already available in several markets. According to MarketScreener and Reuters, Wegovy in pill form has quickly captured a dominant share of the oral obesity space globally, with Reuters stating that Novo-Nordisk executives estimated a 90% share of the oral obesity market for the Wegovy pill when discussing second-quarter 2026 earnings. This strong uptake is further echoed by Seeking Alpha's data on prescription volumes, which show more than 5 million oral Wegovy prescriptions and about 265,000 weekly prescriptions by mid-July 2026.

For Novo-Nordisk, each incremental launch market for Wegovy adds not only direct revenue but also reinforces the brand's recognition among physicians and patients. In Germany, coverage by outlets such as n-tv and ZDF Heute on September 1, 2026 emphasizes that semaglutide tablets for weight loss are now available in pharmacies, marking the first time a GLP-1 weight-loss tablet becomes accessible on a broad basis in the country. These narratives suggest that patient demand is likely to be robust, and they support the company's strategic decision to bring the oral obesity treatment to a large European healthcare system where obesity and related metabolic conditions are a significant public health issue.

Novo-Nordisk stock price and investor perspective

From a market perspective, Novo-Nordisk shares currently trade near recent levels but below their average analyst price target. MarketScreener information compiled on September 1, 2026 shows a last closing price of 292.40 DKK for the primary listing, with indicative intraday quotes around 291.98 DKK to 292.90 DKK on the same date and a market capitalization of approximately DKK 201 billion, equivalent to about USD 1,031 billion. With the average analyst price target at 309.73 DKK, the current price of around 292.40 DKK sits roughly 6% below the consensus target, indicating that analysts on average still project modest upside from current levels. For DACH investors accessing Novo-Nordisk via its Cboe Europe listing under the ticker 0QIU, the cross-market share price stands at 43.70 EUR as of August 31, 2026, providing a euro-denominated reference.

Novo-Nordisk stock at a glance

• Company: Novo-Nordisk A/S
• ISIN: DK0062498333
• Ticker: 0QIU
• Trading venue: Cboe Europe
• Price (as of August 31, 2026, 17:30): 43.70 EUR
• Market capitalization: 201,000,000,000 DKK (as of September 1, 2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: OMX Copenhagen 25